8-K: Bionano Genomics Reports Preliminary Q4 and Full-Year 2024 Results, Revenue Declines Amid Restructuring

Bionano Genomics announced preliminary unaudited results for Q4 and full-year 2024, showing a revenue decrease due to the discontinuation of clinical service products, but also highlighting progress in OGM adoption and cost reduction efforts.

Summary

• Bionano Genomics reported preliminary unaudited financial results for the fourth quarter and full year of 2024.
• Q4 2024 revenue is expected to be between $7.9 and $8.1 million, a decrease of approximately 25% compared to Q4 2023.
• This decrease is primarily due to the discontinuation of clinical service products in 2024.
• However, Q4 2024 revenue is expected to grow 30-33% compared to Q3 2024.
• Full year 2024 revenue is expected to be between $30.5 and $30.7 million, a decrease of approximately 15% compared to 2023.
• Excluding discontinued services, full year 2024 revenue is estimated to be between $28.9 and $29.1 million, compared to $29.1 million in 2023.
• The installed base of optical genome mapping (OGM) systems reached 371 by the end of 2024, a 14% increase from 2023.
• Nanochannel array flowcells sold in Q4 2024 are expected to be 8,058, a 1% increase over Q4 2023.
• The company has reduced annualized operating costs by approximately $100 million since May 2023.
• Bionano restructured its debt at year-end and raised capital in early January 2025 to extend its cash runway.

Sentiment

Score: 5

Explanation: The document presents a mixed picture with significant revenue declines but also positive developments in cost reduction, technology advancements, and debt restructuring. The overall sentiment is neutral to slightly negative due to the financial challenges.

Positives

• The installed base of OGM systems grew by 14% year-over-year, indicating increased adoption of their technology.
• Nanochannel array flowcell sales saw a slight increase, suggesting continued usage of their systems.
• The company has significantly reduced operating costs by approximately $100 million since May 2023.
• The release of the Stratys system is expected to increase data generation rates four-fold.
• The AMA established a category I CPT code for OGM, which should help with reimbursement.
• Debt restructuring and capital raises have extended the company's cash runway.

Negatives

• Q4 2024 revenue is expected to decrease by approximately 25% compared to Q4 2023.
• Full year 2024 revenue is expected to decrease by approximately 15% compared to 2023.
• The revenue decrease is primarily due to the discontinuation of clinical service products.
• The company's cash, cash equivalents, and available-for-sale securities as of December 31, 2024 were approximately $20.9 million, with $11.4 million subject to restrictions.

Risks

• The preliminary financial results are subject to further adjustments, including potential impairments and write-downs.
• The company is still in the process of completing its year-end close and review procedures.
• Adverse geopolitical and macroeconomic events could impact the business and the global economy.
• The company faces challenges in developing, manufacturing, and commercializing products.
• Bionano needs to manage costs and obtain additional financing to continue as a going concern.
• Failure to comply with Nasdaq Listing Rules could adversely affect the company's ability to raise capital.
• There is a risk that the company may seek relief under applicable insolvency laws if it fails to obtain additional financing.

Future Outlook

Bionano aims to improve margins, extend its cash runway, and reach a potential pathway to profitability by continuing to drive OGM adoption, leveraging the new CPT code, and implementing cost-saving measures. The company expects the Stratys system and VIA software to increase throughput and simplify data analysis.

Management Comments

• Erik Holmlin, PhD, president and chief executive officer, stated that 2024 was a year of substantial change focused on restructuring and advancing OGM and VIA software.
• Erik Holmlin noted consistent progress in the business with acceptance and adoption of OGM and VIA software.
• Mark Adamchak, principal accounting officer, emphasized the company's focus on financial discipline and implementing actionable processes to improve margins and extend the cash runway.

Industry Context

The announcement reflects a challenging period for Bionano as it transitions away from clinical services and focuses on its core OGM technology. The establishment of a CPT code for OGM is a significant positive development that could drive adoption. The company's cost-cutting measures are in line with the broader trend of biotech companies focusing on profitability and cash management.

Comparison to Industry Standards

• Bionano's revenue decline contrasts with some other genomics companies that have seen growth, but the company's focus on cost reduction and new product launches is a common strategy in the industry.
• Companies like Pacific Biosciences and Illumina, while having different technologies, are also focused on expanding their market share in the genomics space.
• The 14% growth in OGM system installations is a positive sign, but the overall revenue decline highlights the challenges of transitioning to a new business model.
• The establishment of a CPT code for OGM is a significant advantage for Bionano, as it addresses a key barrier to adoption in the clinical market, similar to how other companies have benefited from favorable reimbursement policies for their technologies.

Stakeholder Impact

• Shareholders may be concerned about the revenue decline but encouraged by the cost-cutting measures and technology advancements.
• Employees may have experienced changes due to the restructuring and cost reduction efforts.
• Customers may benefit from the new Stratys system and VIA software, which offer increased throughput and simplified analysis.
• Suppliers may be impacted by the company's cost-cutting measures.
• Creditors may be impacted by the debt restructuring.

Next Steps

• Bionano will complete its customary year-end close and review procedures.
• The company will continue to focus on financial discipline and implementing actionable processes to improve margins and extend its cash runway.
• Bionano will continue to drive OGM adoption by potential customers for routine use in genomic analysis.
• The company will continue to advance OGM and VIA software as replacements for legacy workflows.

Key Dates

Keywords

Optical Genome Mapping, OGM, Genomics, Bionano Genomics, Financial Results, Revenue, Cost Reduction, Stratys System, VIA Software, CPT Code, Debt Restructuring, Capital Raise